Opportunity Information: Apply for RFA CA 13 502
Apply for RFA CA 13 502
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Limited Competition Pediatric Brain Tumor Consortium (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jun 19, 2013 and posted on Jun 19, 2013.
- Applicants must submit their applications by Sep 16, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,590,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,590,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Only the current awardees of Pediatric Brain Tumor Consortium funded under RFA CA 08 026 are eligible to apply under this Limited Competition FOA. Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Limited Competition Pediatric Brain Tumor Consortium (UM1) funding opportunity (RFA-CA-13-502) is a National Institutes of Health (NIH) cooperative agreement designed to continue federal support for the Pediatric Brain Tumor Consortium (PBTC). The PBTC is positioned as a specialized clinical trials network focused on moving promising, laboratory-developed therapies into early phase clinical testing for children with primary brain tumors. The central purpose is to speed translation from bench to bedside in areas where current treatments still fall short, both in terms of survival and long-term quality of life for pediatric patients.
A major driver behind the FOA is the persistent high mortality seen in several pediatric brain tumor subtypes, including diffuse intrinsic pontine gliomas (DIPG), malignant supratentorial gliomas, and biologically high-risk medulloblastomas and ependymomas. In addition to mortality concerns, NIH highlights that many children who do survive standard therapies experience substantial functional impairments, underscoring the need for new approaches that are not only more effective but also less damaging. Within the broader NIH pediatric brain tumor research portfolio, the PBTC is described as filling a distinct niche because it can evaluate multiple innovative agents and strategies in early phase trials, acting as a translational bridge between discovery science and clinical application.
This is a limited competition announcement, meaning it does not accept applications from the general research community. It solicits only a single application, and eligibility is restricted exclusively to the current PBTC awardee funded under the prior initiative (RFA-CA-08-026). Foreign institutions are not eligible, and non-U.S. components of U.S. organizations are also excluded. In addition, foreign components (as defined by the NIH Grants Policy Statement) are not allowed, reinforcing that the work supported under this FOA must be conducted within eligible U.S.-based organizational structures.
The award mechanism is a cooperative agreement (UM1), which typically indicates substantial involvement by NIH staff in collaboration with the awardee compared with a standard grant. While the FOA summary does not spell out specific scientific aims or trial requirements in the excerpt provided, the intent is clearly oriented toward sustaining an established, coordinated clinical trials capability that can prioritize and test new therapeutic concepts efficiently in pediatric neuro-oncology, particularly at the early phase stage where feasibility, safety, dosing, and preliminary signals of activity are assessed.
Key administrative details reflect a single-award, consortium-level scale. The estimated total funding is $2,590,000, and the award ceiling is also $2,590,000, indicating the maximum amount NIH expected to commit under this particular announcement. Cost sharing or matching is not required. The opportunity was posted on June 19, 2013, with an original and current closing date of September 16, 2013, and it was archived on October 17, 2013. The associated CFDA number listed is 93.395 (Cancer Treatment Research), aligning the program squarely with NIH cancer treatment research priorities.
For applicants and readers seeking the full details, NIH provided an additional information link to the official FOA page hosted on the NIH grants site. Support for access or linking issues is routed through the NIH Office of Extramural Research (OER) webmaster contact listed in the announcement.
Frequently Asked Questions (FAQs)
What is the name and number of this funding opportunity?
The opportunity is titled "Limited Competition Pediatric Brain Tumor Consortium (UM1)" and the funding opportunity announcement (FOA) number is RFA-CA-13-502.
Which federal agency is offering this opportunity?
This opportunity is offered by the National Institutes of Health (NIH).
What type of award is being used?
The award mechanism is a cooperative agreement (UM1).
What does a UM1 cooperative agreement generally imply?
A UM1 cooperative agreement typically means NIH staff will have substantial involvement in collaboration with the awardee, compared with a standard grant mechanism.
What is the Pediatric Brain Tumor Consortium (PBTC)?
The PBTC is described as a specialized clinical trials network focused on moving promising, laboratory-developed therapies into early phase clinical testing for children with primary brain tumors.
What is the main purpose of continuing support for the PBTC under this FOA?
The central purpose is to speed translation from bench to bedside for pediatric brain tumor therapies in areas where current treatments still fall short, both for survival and long-term quality of life.
What research or clinical niche does PBTC fill within NIH's pediatric brain tumor portfolio?
Within the broader NIH pediatric brain tumor research portfolio, PBTC is described as filling a distinct niche by evaluating multiple innovative agents and strategies in early phase trials and serving as a translational bridge between discovery science and clinical application.
What types of trials are emphasized in this opportunity?
The excerpt emphasizes early phase clinical testing, where feasibility, safety, dosing, and preliminary signals of activity are assessed.
Why did NIH highlight the need for this consortium-based effort?
NIH cites persistent high mortality in several pediatric brain tumor subtypes and also underscores that many survivors of standard therapies experience substantial functional impairments. This supports the need for approaches that are both more effective and less damaging.
Which pediatric brain tumor subtypes are specifically referenced as having high mortality or high risk?
The announcement references diffuse intrinsic pontine gliomas (DIPG), malignant supratentorial gliomas, and biologically high-risk medulloblastomas and ependymomas.
Is this an open competition?
No. This is a limited competition announcement and it does not accept applications from the general research community.
How many applications does the FOA solicit?
The announcement solicits only a single application.
Who is eligible to apply?
Eligibility is restricted exclusively to the current PBTC awardee funded under the prior initiative (RFA-CA-08-026).
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible under this FOA.
Are non-U.S. components of U.S. organizations allowed?
No. Non-U.S. components of U.S. organizations are excluded.
Are foreign components permitted under this FOA?
No. Foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
Does this FOA require cost sharing or matching?
No. Cost sharing or matching is not required.
What is the estimated total funding available under this announcement?
The estimated total funding is $2,590,000.
What is the maximum award amount (ceiling) stated in the announcement?
The award ceiling is $2,590,000, which is the maximum amount NIH expected to commit under this announcement.
When was this opportunity posted?
The opportunity was posted on June 19, 2013.
What was the closing date for applications?
The original and current closing date listed is September 16, 2013.
Is this opportunity still active?
No. The opportunity was archived on October 17, 2013.
What CFDA number is associated with this opportunity?
The associated CFDA number listed is 93.395, which is labeled as Cancer Treatment Research.
What general program area does this funding align with?
Based on the CFDA listing and the FOA description, it aligns with NIH cancer treatment research priorities, specifically focused on pediatric brain tumor clinical trials.
Where can someone find the official FOA details?
NIH provided an additional information link to the official FOA page hosted on the NIH grants site.
Who should be contacted for technical issues accessing the FOA link or webpage?
The announcement routes support for access or linking issues through the NIH Office of Extramural Research (OER) webmaster contact listed in the announcement.
Browse more opportunities from the same category: Education Health
Next opportunity: Person Centered Outcomes Research Resource (U2C)
Previous opportunity: Limited Competition Adult Brain Tumor Consortium (ABTC) (UM1)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 13 502
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 13 502) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Trials and Interventional Studies of Non Pharmacological Approaches to Managing Pain and Co Morbid Conditions in U.S. Military Personnel, Veterans, and their Families (R01) Apply for RFA AT 14 003 Funding Number: RFA AT 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pilot and Feasibility Studies of Non Pharmacological Approaches to Managing Pain and Co Morbid Conditions in U.S. Military Personnel, Veterans, and their Families (R34) Apply for RFA AT 14 004 Funding Number: RFA AT 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Health Services and Observational Studies of Non Pharmacological Approaches to Managing Pain and Co Morbid Conditions in U.S. Military Personnel, Veterans, and their Families (R01) Apply for RFA AT 14 005 Funding Number: RFA AT 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Program Project Grant Applications (P01) Apply for PAR 13 259 Funding Number: PAR 13 259 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synergizing Omic and Symptom Science (R15) Apply for PA 13 265 Funding Number: PA 13 265 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Synergizing Omic and Symptom Science (R01) Apply for PA 13 264 Funding Number: PA 13 264 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Use Disorders (U01) Apply for PAR 13 270 Funding Number: PAR 13 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $5,000,000 |
| Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (R01) Apply for RFA DA 14 014 Funding Number: RFA DA 14 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (Admin Supp) Apply for PA 13 275 Funding Number: PA 13 275 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Abuse Resistant and Abuse Deterrent Formulations and Devices to Avoid the Abuse, Misuse and Diversion of Prescription Opioids by Patients (SBIR)(R43/R44) Apply for RFA DA 14 013 Funding Number: RFA DA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PAR 13 282 Funding Number: PAR 13 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| NLM Career Development Award in Biomedical Informatics (K01) Apply for PAR 13 284 Funding Number: PAR 13 284 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Evidence Effective Palliative/End of Life Care Interventions (R01) Apply for PAR 13 289 Funding Number: PAR 13 289 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Express Research Grants in Biomedical Informatics (R01) Apply for PAR 13 300 Funding Number: PAR 13 300 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 13 294 Funding Number: PAR 13 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 297 Funding Number: PAR 13 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 298 Funding Number: PAR 13 298 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 317 Funding Number: PAR 13 317 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 318 Funding Number: PAR 13 318 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| National Cancer Institute Program Project Applications (P01) Apply for PAR 13 321 Funding Number: PAR 13 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 13 502", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.